CurrentBlue Cross Blue Shield - IowaPolicy 05.02.67

Ketamine injection coverage for anesthesia and chronic pain (CRPS)

Defines medical necessity and coverage for ketamine hydrochloride injection: covered for specified anesthesia uses and for Complex Regional Pain Syndrome (CRPS) up to 12 weeks; investigational and not covered for psychiatric disorders, most chronic pain conditions, and chronic daily headache. Includes clinical rationale, safety, literature review, and billing guidance.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyKetamine injection coverage for anesthesia and chronic pain (CRPS)

Policy CodePolicy 05.02.67

Change TypeClarified

Effective DateMar 26, 2020

Next Review Date

Key ActionVerify individual member benefits and any exclusions prior to treatment.

POLICY UPDATE CHANGES

Policy defines ketamine as medically necessary for anesthesia uses and for CRPS up to 12 weeks, and investigational for psychiatric disorders, chronic pain (other than CRPS), and chronic daily headache.

4Covered Indications Listed

3Not Covered Indication Categories

1Billing HCPCS Code Listed

Coverage Summary

Overview: This policy (Policy # 05.02.67; effective 2020-03-26; last reviewed 2025-06) defines coverage for ketamine hydrochloride injection. Coverage is mixed: ketamine is considered medically necessary and may be covered for FDA-labeled anesthetic uses (diagnostic and surgical procedures not requiring skeletal muscle relaxation; induction of anesthesia; supplemental anesthesia for low-potency agents) and is covered for Complex Regional Pain Syndrome (CRPS) up to 12 weeks. Ketamine is considered investigational and not covered for psychiatric disorders, most chronic pain indications (other than CRPS), and chronic daily headache.

Medical Necessity / Coverage Criteria

Medically Necessary / Covered Indications

Ketamine is considered medically necessary and may be covered when any of the following indications are met:

Anesthesia - diagnostic/surgical: Anesthesia for diagnostic and surgical procedures that do not require skeletal muscle relaxation
Anesthesia - induction: Induction of anesthesia prior to administration of other general anesthetic agents
Anesthesia - supplemental: Supplemental anesthesia for low-potency agents, such as nitrous oxide
CRPS treatment: Treatment of Complex Regional Pain Syndrome (CRPS) for up to 12 weeks

Investigational / Not Covered Indications

Ketamine is considered investigational and not covered when used for any of the following:

Psychiatric disorders (including, but not limited to depression, bipolar disorder, obsessive compulsive disorder (OCD), autism spectrum disorder, and posttraumatic stress disorder)
Chronic pain (non-CRPS): Chronic pain (including but not limited to mixed neuropathic pain, fibromyalgia, cancer pain, spinal pain)
Chronic daily headache (includes chronic migraine, new daily persistent headache, hemicranias continua, and chronic tension-type headache)
All other indications not listed as covered (considered experimental/investigational)

Provider Actions & Billing Guidance

Documentation Required

Verify member benefits and contract applicability

Verify individual member benefits and any contract exclusions, limitations, or exceptions prior to treatment. Benefit determinations are based on the applicable contract language in effect at the time of service and may vary by contract.

Documentation Required

Limit CRPS treatment duration

Document a diagnosis of Complex Regional Pain Syndrome (CRPS) when requesting coverage for ketamine treatment and limit the course of treatment to up to 12 weeks per policy.

Billing Rule

Report drug as J3490 if applicable

Use appropriate procedure and diagnosis coding for provider services. For the drug itself, J3490 (Unclassified drugs) is listed for unclassified drug billing when applicable.

HCPCS: J3490 (Unclassified drugs)
Report provider services with appropriate CPT, HCPCS, Revenue, and ICD diagnostic codes

Denial Risk

Not covered for psychiatric, most chronic pain, and chronic daily headache

Ketamine use for psychiatric disorders, most chronic pain indications (other than CRPS), and chronic daily headache is considered investigational and not covered; claims for these indications may be denied.

Background & Evidence Summary

Background: The policy notes that ketamine hydrochloride injection is FDA-approved for anesthesia (diagnostic and surgical procedures not requiring skeletal muscle relaxation; induction of anesthesia; and to supplement low-potency agents such as nitrous oxide). Evidence for off-label uses (psychiatric disorders, chronic pain, migraine/chronic daily headache) is limited, based on small, low-quality or uncontrolled studies with insufficient data on long-term safety and efficacy. Known safety risks include psychological effects (ranging from pleasant dissociative states to hallucinations and delirium), substance abuse potential (schedule III), hepatotoxicity, and urinary cystitis. Guidelines and reviews (e.g., ASRA/AAP/ASA, APA) highlight variable/limited evidence across chronic pain conditions and call for caution due to lack of long-term data.

Guideline summary / Evidence (brief)

Definitions (policy text / exact)

Revision History

2020-03-26policy_effective

Policy effective date: defines ketamine as medically necessary/covered for anesthesia indications (diagnostic and surgical procedures not requiring skeletal muscle relaxation; induction of anesthesia; supplemental anesthesia with low-potency agents) and for treatment of Complex Regional Pain Syndrome (CRPS) for up to 12 weeks.

2020-03-26policy_effective

Policy declares ketamine investigational and not covered for psychiatric disorders (including but not limited to depression, bipolar disorder, OCD, autism spectrum disorder, and PTSD), chronic pain indications other than CRPS (including mixed neuropathic pain, fibromyalgia, cancer pain, spinal pain), and chronic daily headache (chronic migraine, new daily persistent headache, hemicranias continua, chronic tension-type headache).

2025-06policy_reviewLatest

Policy reviewed in June 2025; review affirms FDA-approved anesthetic indications and compendial CRPS indication (coverage up to 12 weeks) and maintains investigational status for psychiatric disorders, most chronic pain conditions, and chronic daily headache, citing limited, low-quality evidence and safety concerns (psychological effects, abuse potential, hepatotoxicity, urinary cystitis).

clarificationLatest

Clarification: policy defines ketamine as medically necessary for anesthesia uses and for CRPS up to 12 weeks, and investigational for psychiatric disorders, chronic pain (other than CRPS), and chronic daily headache. This statement is present in the policy body; no separate revision log indicates a clinical change. (Non-material clarification.)